CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 254 enrolled
Drug / intervention
Lebrikizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04626297
NCT04626297Phase 3Completed
CompareCT.gov

A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company·interventional·Posted Nov 12, 2020·Updated Oct 17, 2023

In Brief

A Phase 3 clinical trial evaluating Lebrikizumab and Placebo for Atopic Dermatitis. Completed, enrolled 254 participants across 85 sites.

Detailed Summary

The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedNov 12, 2020
Enrollment StartNov 17, 2020
Primary CompletionAug 3, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.6 years ago

Interventions

Lebrikizumabdrug

Given SC

Placebodrug

Given SC